These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 36855956)

  • 1. Trispecific antibodies for cancer immunotherapy.
    Yao Y; Hu Y; Wang F
    Immunology; 2023 Aug; 169(4):389-399. PubMed ID: 36855956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy.
    Tapia-Galisteo A; Compte M; Álvarez-Vallina L; Sanz L
    Theranostics; 2023; 13(3):1028-1041. PubMed ID: 36793863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cancer therapeutic trispecific antibodies recruiting both T and natural killer cells to cancer cells.
    Kimura K; Kuwahara A; Suzuki S; Nakanishi T; Kumagai I; Asano R
    Oncol Rep; 2023 Dec; 50(6):. PubMed ID: 37859608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins.
    Debelec-Butuner B; Quitt O; Schreiber S; Momburg F; Wisskirchen K; Protzer U
    Front Immunol; 2022; 13():1029214. PubMed ID: 36405686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building blocks for bispecific and trispecific antibodies.
    Wu X; Demarest SJ
    Methods; 2019 Feb; 154():3-9. PubMed ID: 30172007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody variable region engineering for improving cancer immunotherapy.
    Lou H; Cao X
    Cancer Commun (Lond); 2022 Sep; 42(9):804-827. PubMed ID: 35822503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current landscape and future directions of bispecific antibodies in cancer immunotherapy.
    Wei J; Yang Y; Wang G; Liu M
    Front Immunol; 2022; 13():1035276. PubMed ID: 36389699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer.
    Huan T; Guan B; Li H; Tu X; Zhang C; Tang B
    Hum Vaccin Immunother; 2023 Aug; 19(2):2256904. PubMed ID: 37772505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and clinical application of bispecific antibody in the treatment of colorectal cancer.
    Balibegloo M; Rezaei N
    Expert Rev Clin Immunol; 2020 Jul; 16(7):689-709. PubMed ID: 32536227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Her2/VEGFR2/CD3 trispecific antibody with an optimal structural design showed improved T-cell-redirecting antitumor efficacy.
    Liu D; Qi X; Wei X; Zhao L; Wang X; Li S; Wang Z; Shi L; Xu J; Hong M; Liu Z; Zhao L; Wang X; Zhang B; Zhang Y; Wang F; Cao YJ
    Theranostics; 2022; 12(18):7788-7803. PubMed ID: 36451856
    [No Abstract]   [Full Text] [Related]  

  • 11. Bispecific T-cell engagers non-covalently decorated drug-loaded PEGylated nanocarriers for cancer immunochemotherapy.
    Cheng WJ; Chuang KH; Lo YJ; Chen M; Chen YJ; Roffler SR; Ho HO; Lin SY; Sheu MT
    J Control Release; 2022 Apr; 344():235-248. PubMed ID: 35288168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bi/tri-specific antibodies (HN-Fc-CD16 and HN-Fc-IL-15-CD16) cross-linking natural killer (NK)-CD16 and Newcastle Disease Virus (NDV)-HN, enhanced NK activation for cancer immunotherapy.
    Bahrololoumi Shapourabadi M; Momburg F; Roohvand F; Jarahian M; Mohajel N; Arashkia A; Hajari Taheri F; Abbasalipour M; Azadmanesh K
    Int Immunopharmacol; 2021 Jul; 96():107762. PubMed ID: 34162140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
    Acheampong DO
    Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific Antibody Armed T Cells to Target Cancer Cells.
    Thakur A; Lum LG; Mittal S
    Methods Mol Biol; 2018; 1722():117-126. PubMed ID: 29264802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bringing Together the Power of T Cell Receptor Mimic and Bispecific Antibodies for Cancer Immunotherapy: Still a Long Way to Go.
    Shivarov V; Blazhev G
    Monoclon Antib Immunodiagn Immunother; 2021 Apr; 40(2):81-85. PubMed ID: 33900820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.
    Gantke T; Weichel M; Herbrecht C; Reusch U; Ellwanger K; Fucek I; Eser M; Müller T; Griep R; Molkenthin V; Zhukovsky EA; Treder M
    Protein Eng Des Sel; 2017 Sep; 30(9):673-684. PubMed ID: 28981915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
    Thakur A; Lum LG
    Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.